Haematex产品代理
Haematex产品代理
我们的项目包括开发已获得 Diagnostica Stago 许可的促凝血磷脂（PPL 测试）的 Xa 因子激活凝血测试 (XACT)。这可以检测癌症和（可能）心脏病中的血栓形成风险。
我们还协助 Hyphen BioMed、Sysmex、Enzyme Research Lab 等成功的研发项目。我们开发了胶原蛋白、鞣花酸复合物和其他化合物的方法，可用于凝血测试和血液/生物材料研究。
我们特别感兴趣的是开发改进的出血和凝血障碍测试。特别适用于获得性和治疗性凝血抑制剂。因此，我们拥有针对所有新型直接口服抗凝剂 (DOAC) 的新型 APTT 试剂和基于 RVV 的测试。
最近，我们开发了 DOAC Stop™，这是一种活性炭产品，可专门从患者样本中提取 DOAC，从而即使最初存在 DOAC 也能进行有效的常规测试。我们很高兴与任何志同道合的研究人员互动。
Haematex Research Pty Ltd was formed in Sydney in 2004 by scientists from Australian hospital laboratories and Gradipore/Life Diagnostics. Gradipore had international success in commercializing the dilute Russells viper venom (RVV) test for lupus anticoagulants and we have developed this further to a liquid stable and more specific system.
Our projects have included developing a factor Xa activated clotting test (XACT) for procoagulant phospholipid (PPL test) licenced to Diagnostica Stago. This detects prothrombotic risk in cancer and (probably) cardiac disease.
We have also assisted Hyphen BioMed, Sysmex, Enzyme Research Lab and others in successful R&D projects. We have
developed methods for collagen, ellagic acid complex and other compounds useful in coagulation testing and blood/biomaterials research.
Our special interest is in the development of improved tests for bleeding and clotting disorders. Especially for acquired and therapeutic coagulation inhibitors. Thus, we have novel APTT reagents and a RVV-based test for all the new direct oral anticoagulants (DOACs).
Most recently we have developed DOAC Stop™, an activated carbon product which specifically withdraws DOACs from patient samples, thus allowing valid routine tests to be carried out despite the initial presence of DOACs. We would be delighted to interact with any like-minded researchers.
